Trial Outcomes & Findings for A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir (NCT NCT03234036)

Last Updated: 2020-10-28

Results Overview

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet and capsule formulation in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population who had at least 1 non-missing pharmacokinetic assessment (Non-quantifiable \[NQ\] values were considered as non-missing values).

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

26 participants

Primary outcome timeframe

Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1 and 2 of Part 1

Results posted on

2020-10-28

Participant Flow

This two-part study assessed the relative bioavailability and food effect of a novel tablet formulation of boosted-GSK2838232 compared to capsule along with safety and pharmacokinetics of repeated once-daily doses of non-boosted GSK2838232. This study was conducted at a single center in the United States.

Participants received GSK2838232 200 milligrams (mg)/ritonavir as capsule or tablet formulation in Part 1 and GSK2838232 500 mg or placebo in Part 2. A total number of 16 participants were enrolled in Part 1 of the study and 10 participants were enrolled in Part 2. In total, 26 participants were enrolled in the study.

Participant milestones

Participant milestones
Measure	GSK2838232 Capsule Fed/Tablet Fed/Tablet Fasted With Ritonavir Eligible participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule administered under fed conditions in treatment period 1 along with ritonavir 100 mg tablet to be taken with water in fed condition, followed by a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet administered under fed conditions in treatment period 2 along with ritonavir 100 mg tablet to be taken with water in fed condition, followed by a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet administered under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition. Treatment period 1 and 2 were separated by a wash-out period of 10 days. Treatment period 2 and 3 were separated by 15 days wash-out period.	GSK2838232 Tablet Fed/Capsule Fed/Tablet Fasted With Ritonavir Eligible participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet administered under fed conditions in treatment period 1 along with ritonavir 100 mg tablet to be taken with water in fed condition, followed by a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule administered under fed conditions in treatment period 2 along with ritonavir 100 mg tablet to be taken with water in fed condition, followed by a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet administered under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition. Treatment period 1 and 2 were separated by a wash-out period of 10 days. Treatment period 2 and 3 were separated by 15 days wash-out period.	Part 2: Placebo Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.	Part 2: GSK2838232 500 mg Tablet Fed Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.
Part 1: Treatment Period 1(Up to 7 Days) STARTED	8	8	0	0
Part 1: Treatment Period 1(Up to 7 Days) COMPLETED	8	8	0	0
Part 1: Treatment Period 1(Up to 7 Days) NOT COMPLETED	0	0	0	0
Part 1:Washout Period 1 (Up to 10 Days) STARTED	8	8	0	0
Part 1:Washout Period 1 (Up to 10 Days) COMPLETED	7	7	0	0
Part 1:Washout Period 1 (Up to 10 Days) NOT COMPLETED	1	1	0	0
Part 1: Treatment Period 2(Up to 7 Days) STARTED	7	7	0	0
Part 1: Treatment Period 2(Up to 7 Days) COMPLETED	7	7	0	0
Part 1: Treatment Period 2(Up to 7 Days) NOT COMPLETED	0	0	0	0
Part 1:Washout Period 2 (Up to 15 Days) STARTED	7	7	0	0
Part 1:Washout Period 2 (Up to 15 Days) COMPLETED	7	7	0	0
Part 1:Washout Period 2 (Up to 15 Days) NOT COMPLETED	0	0	0	0
Part 1:Treatment Period 3 (Up to 7 Days) STARTED	7	7	0	0
Part 1:Treatment Period 3 (Up to 7 Days) COMPLETED	7	7	0	0
Part 1:Treatment Period 3 (Up to 7 Days) NOT COMPLETED	0	0	0	0
Part 2 (Up to 25 Days) STARTED	0	0	3	7
Part 2 (Up to 25 Days) COMPLETED	0	0	3	7
Part 2 (Up to 25 Days) NOT COMPLETED	0	0	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	GSK2838232 Capsule Fed/Tablet Fed/Tablet Fasted With Ritonavir Eligible participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule administered under fed conditions in treatment period 1 along with ritonavir 100 mg tablet to be taken with water in fed condition, followed by a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet administered under fed conditions in treatment period 2 along with ritonavir 100 mg tablet to be taken with water in fed condition, followed by a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet administered under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition. Treatment period 1 and 2 were separated by a wash-out period of 10 days. Treatment period 2 and 3 were separated by 15 days wash-out period.	GSK2838232 Tablet Fed/Capsule Fed/Tablet Fasted With Ritonavir Eligible participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet administered under fed conditions in treatment period 1 along with ritonavir 100 mg tablet to be taken with water in fed condition, followed by a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule administered under fed conditions in treatment period 2 along with ritonavir 100 mg tablet to be taken with water in fed condition, followed by a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet administered under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition. Treatment period 1 and 2 were separated by a wash-out period of 10 days. Treatment period 2 and 3 were separated by 15 days wash-out period.	Part 2: Placebo Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.	Part 2: GSK2838232 500 mg Tablet Fed Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.
Part 1:Washout Period 1 (Up to 10 Days) Adverse Event	1	1	0	0

Baseline Characteristics

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1: All Participants Receiving GSK2838232/Ritonavir n=16 Participants Eligible participants were assigned to treatment sequence AB or BA where A=single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule under fed condition and B=single dose of GSK2838232 200 mg (as 4 x 50 mg) tablet formulations administered under fed condition in treatment periods 1 and 2 along with ritonavir 100 mg to be taken with water in fed condition. Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet administered under fasted conditions in treatment period 3 along with ritonavir 100 mg to be taken with water in fasted condition. Treatment periods 1 and 2 were separated by a wash-out period of 10 days. Treatment periods 2 and 3 were separated by a wash-out period of 15 days.	Part 2: Placebo n=3 Participants Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.	Part 2: GSK2838232 500 mg Tablet Fed n=7 Participants Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.	Total n=26 Participants Total of all reporting groups
Age, Continuous	36.3 Years STANDARD_DEVIATION 9.54 • n=5 Participants	41.0 Years STANDARD_DEVIATION 9.64 • n=7 Participants	34.6 Years STANDARD_DEVIATION 7.81 • n=5 Participants	36.38 Years STANDARD_DEVIATION 9.30 • n=4 Participants
Sex: Female, Male Female	9 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	10 Participants n=4 Participants
Sex: Female, Male Male	7 Participants n=5 Participants	3 Participants n=7 Participants	6 Participants n=5 Participants	16 Participants n=4 Participants
Race/Ethnicity, Customized BLACK OR AFRICAN AMERICAN	8 Participants n=5 Participants	2 Participants n=7 Participants	6 Participants n=5 Participants	16 Participants n=4 Participants
Race/Ethnicity, Customized WHITE - WHITE/CAUCASIAN/EUROPEAN HERITAGE	6 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	7 Participants n=4 Participants
Race/Ethnicity, Customized MULTIPLE-ASIAN & BLACK OR AFRICAN AMERICAN	2 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	2 Participants n=4 Participants
Race/Ethnicity, Customized AMERICAN INDIAN OR ALASKA NATIVE	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants

PRIMARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1 and 2 of Part 1

Population: Pharmacokinetic Population

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State	4672.28 Hours*nanogram per milliliter Geometric Coefficient of Variation 40.68	4437.98 Hours*nanogram per milliliter Geometric Coefficient of Variation 30.83	—

PRIMARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1 and 2 of Part 1

Population: Pharmacokinetic Population

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 1: Maximum Observed Concentration (Cmax) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State	109.054 Nanograms per milliliter Geometric Coefficient of Variation 48.01	118.118 Nanograms per milliliter Geometric Coefficient of Variation 27.59	—

PRIMARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1

Population: Pharmacokinetic Population

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet formulation in fed and fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=14 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 1: AUC (0-infinity) Following Administration of GSK2838232 Tablet in Fasted and Fed State	4437.98 Hours*nanogram per milliliter Geometric Coefficient of Variation 30.83	1816.27 Hours*nanogram per milliliter Geometric Coefficient of Variation 36.42	—

PRIMARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1

Population: Pharmacokinetic Population

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=14 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 1: Cmax Following Administration of GSK2838232 Tablet in Fasted and Fed State	118.118 Nanograms per milliliter Geometric Coefficient of Variation 27.59	50.437 Nanograms per milliliter Geometric Coefficient of Variation 35.61	—

PRIMARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1

Population: Pharmacokinetic Population

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=14 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 1: Time of Occurrence of Cmax (Tmax) Following Administration of GSK2838232 Tablet in Fasted and Fed State	5.983 Hours Interval 2.0 to 24.03	3.508 Hours Interval 2.0 to 11.97	—

PRIMARY outcome

Timeframe: Up to 25 days

Population: Safety Population

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/ birth defect, is associated with liver injury or impaired liver function or any other situations as per medical or scientific judgment. Safety Population comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment. Number of participants with SAEs and common non-SAEs (\>=5%) are presented.

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=3 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs Any SAE	0 Participants	0 Participants	—
Part 2: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs Any non-SAE	1 Participants	0 Participants	—

PRIMARY outcome

Timeframe: Up to 25 days

Population: Safety Population

Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were \< 0.075 or \>0.54 proportion of red blood cells in blood for hematocrit, \<25 or \>180 grams per liter (g/L) for hemoglobin, \< 3 or \>20 cells per liter (cells/L) for leukocytes, 0.8 x10\^9 cells/L for lymphocytes, 1.5 x10\^9 cells/L for neutrophils, and \<100 or \>550 cells/L for platelets. Participants were counted in the worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (example given \[e.g.\], High to High), or whose value became within range, were recorded in the "To within Range or No Change" category.

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=3 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Hematocrit; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Leukocytes; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Lymphocytes; To within Range or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Lymphocytes; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Neutrophils; To Low	1 Participants	1 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Platelets; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Lymphocytes; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Hematocrit; To within Range or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Hematocrit; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Hemoglobin; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Hemoglobin; To within Range or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Hemoglobin; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Leukocytes; To within Range or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Leukocytes; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Neutrophils; To within Range or No Change	2 Participants	6 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Neutrophils; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Platelets; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria Platelets; To within Range or No Change	3 Participants	7 Participants	—

PRIMARY outcome

Timeframe: Up to 25 days

Population: Safety Population

Blood samples were collected from participants for analysis of following clinical chemistry parameters; glucose, alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), bilirubin, calcium, potassium and sodium. PCI ranges were \<30 g/L for albumin, \<2 or \>2.75 millimoles per liter (mmol/L) for calcium, \<3 or \>9 mmol/L for glucose, \>=2 times Upper limit of Normal (ULN) units per liter (U/L) for ALT, \>=2 times ULN U/L for alkaline phosphatase, \>=2 times ULN U/L for AST, \>=1.5 times ULN micromoles per liter (µmol/L) for bilirubin, \<3 or \>5.5 mmol/L for potassium, and \<130 or \>150 mmol/L for sodium. Participants were counted in the worst case category that their value changes to (low, within range or no change,or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the "To within Range or No Change" category.

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=3 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria ALT; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Glucose; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Glucose; To within Range or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Glucose; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria ALT; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria ALT; To within Range or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Albumin; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Albumin; To within Range or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Albumin; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Alkaline phosphatase; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Alkaline phosphatase; To within Range or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Alkaline phosphatase; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria AST; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria AST; To within Range or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria AST; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Bilirubin; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Bilirubin; To within Range or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Bilirubin; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Calcium; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Calcium; To within Range or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Calcium; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Potassium; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Potassium; To within Range or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Potassium; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Sodium; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Sodium; To within Range or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Sodium; To High	0 Participants	0 Participants	—

PRIMARY outcome

Timeframe: Up to 25 days

Population: Safety Population

Urine samples were collected from participants for analysis of following urinalysis parameters; specific gravity, potential of hydrogen (pH), presence of glucose, protein, occult blood, ketones in urine analyzed by dipstick method. The dipstick test gives results in a semi-quantitative manner. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The reference range is 1.002-1.030. Urine pH is an acid-base measurement. Normal urine has a slightly acid pH (5.0 - 6.0). Participants were counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the "To Normal or No Change" category.

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=3 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Glucose; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Glucose; To Normal or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Glucose; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Glucose; To Abnormal	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Ketones; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Ketones; To Normal or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Ketones; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Ketones; To Abnormal	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Occult blood; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Occult blood; To Normal or No Change	2 Participants	6 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Occult blood; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Occult blood; To Abnormal	1 Participants	1 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Protein; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Protein; To Normal or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Protein; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Protein; To Abnormal	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Specific gravity; To Low	1 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Specific gravity; To Normal or No Change	2 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Specific gravity; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Specific gravity; To Abnormal	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Urine pH; To Low	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Urine pH; To Normal or No Change	3 Participants	7 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Urine pH; To High	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Urine pH; To Abnormal	0 Participants	0 Participants	—

PRIMARY outcome

Timeframe: Day -1; Pre-dose, 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)

Population: Safety Population

Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured in supine position after 10 minutes rest for the participants at indicated time points.

Outcome measures

PRIMARY outcome

Timeframe: Baseline (Day -1) and 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)

Population: Safety Population

SBP and DBP were measured in supine position after 10 minutes rest for participants at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Area Under the Plasma Drug Concentration Time Curve From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State Day 1	895.42 Hours*nanograms per milliliter Geometric Coefficient of Variation 39.08	—	—
Part 2: Area Under the Plasma Drug Concentration Time Curve From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State Day 11	1184.55 Hours*nanograms per milliliter Geometric Coefficient of Variation 35.34	—	—

PRIMARY outcome

Population: Pharmacokinetic Population

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Cmax Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State Day 1	79.575 Nanograms per milliliter Geometric Coefficient of Variation 45.69	—	—
Part 2: Cmax Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State Day 11	94.239 Nanograms per milliliter Geometric Coefficient of Variation 34.24	—	—

PRIMARY outcome

Population: Pharmacokinetic Population

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Observed Concentration at the End of the Dosing Interval (Ctau) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State Day 1	21.620 Nanograms per milliliter Geometric Coefficient of Variation 42.51	—	—
Part 2: Observed Concentration at the End of the Dosing Interval (Ctau) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State Day 11	27.668 Nanograms per milliliter Geometric Coefficient of Variation 41.16	—	—

PRIMARY outcome

Population: Pharmacokinetic Population

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Tmax Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State Day 1	4.000 Hours Interval 2.0 to 8.0	—	—
Part 2: Tmax Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State Day 11	3.500 Hours Interval 1.98 to 6.0	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1 in Part 2

Population: Pharmacokinetic Population

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Tlag is a time delay between drug administration and first observed concentration. Pharmacokinetic parameters were determined using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Lag-time (Tlag) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 1	0.500 Hours Interval 0.0 to 1.0	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2

Population: Pharmacokinetic Population

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: AUC(0-infinity) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11	1816.34 Hours*nanograms per milliliter Geometric Coefficient of Variation 37.32	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2

Population: Pharmacokinetic Population

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Apparent Terminal Phase Half-life (T1/2) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11	23.217 Hours Geometric Coefficient of Variation 37.85	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2

Population: Pharmacokinetic Population

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Time of Last Quantifiable Concentration (Tlast) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11	118.800 Hours Interval 95.1 to 118.85	—	—

SECONDARY outcome

Timeframe: Up to 60 days

Population: Safety Population

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/ birth defect, is associated with liver injury or impaired liver function or any other situations as per medical or scientific judgment. Number of participants with SAEs and common non-SAEs (\>=5%) are presented.

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted n=14 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 1: Number of Participants With SAEs and Non-SAEs Any SAE	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With SAEs and Non-SAEs Any non-SAE	3 Participants	2 Participants	1 Participants

SECONDARY outcome

Timeframe: Up to 60 days

Population: Safety Population

Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were \>0.54 as proportion of red blood cells in blood for hematocrit, \>180 g/L for hemoglobin, \< 3 or \>20 cells/L for leukocytes, 0.8 x10\^9 cells/L for lymphocytes, 1.5 x10\^9 cells/L for neutrophils, and \<100 or \>550 cells/L for platelets. Participants were counted in the worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the "To within Range or No Change" category.

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted n=14 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Hematocrit; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Leukocytes; To within Range or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Neutrophils; To within Range or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Hematocrit; To within Range or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Hematocrit; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Hemoglobin; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Hemoglobin; To within Range or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Hemoglobin; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Leukocytes; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Leukocytes; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Lymphocytes; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Lymphocytes; To within Range or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Lymphocytes; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Neutrophils; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Neutrophils; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Platelets; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Platelets; To within Range or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria Platelets; To High	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Up to 60 days

Population: Safety Population

Blood samples were collected from participants for analysis of following clinical chemistry parameters; glucose, ALT, albumin, alkaline phosphatase, AST, bilirubin, calcium, potassium and sodium. PCI ranges were \<30 g/L for albumin, \<2 or 2.75 mmol/L for calcium, \<3 or \>9 mmol/L for glucose, \>=2 times ULN U/L for ALT, \>=2 times ULN U/L for alkaline phosphatase, \>=2 times ULN U/L for AST, \>=1.5 times ULN µmol/L for bilirubin, \<3 or \>5.5 mmol/L for potassium, and \<130 or \>150 mmol/L for sodium. Participants were counted in the worst case category that their value changes to (low, within range or no change,or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the "To within Range or No Change" category.

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted n=14 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Bilirubin; To within Range or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Glucose; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Glucose; To within Range or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Glucose; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria ALT; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria ALT; To within Range or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria ALT; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Albumin; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Albumin; To within Range or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Albumin; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Alkaline phosphatase; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Alkaline phosphatase; To within Range or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Alkaline phosphatase; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria AST; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria AST; To within Range or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria AST; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Bilirubin; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Bilirubin; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Calcium; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Calcium; To within Range or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Calcium; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Potassium; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Sodium; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Potassium; To within Range or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Potassium; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Sodium; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria Sodium; To within Range or No Change	15 Participants	15 Participants	14 Participants

SECONDARY outcome

Timeframe: Up to 60 days

Population: Safety Population

Urine samples were collected from participants for analysis of following urinalysis parameters; specific gravity, pH, presence of glucose, protein, occult blood, ketones in urine analyzed by dipstick method. The dipstick test gives results in a semi-quantitative manner. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The reference range is 1.002-1.030. Urine pH is an acid-base measurement. Normal urine has a slightly acid pH (5.0 - 6.0). Participants were counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the "To Normal or No Change" category.

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted n=14 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Glucose; To Abnormal	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Specific gravity; To Low	1 Participants	0 Participants	2 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Glucose; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Glucose; To Normal or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Glucose; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Ketones; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Ketones; To Normal or No Change	14 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Ketones; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Ketones To Abnormal	1 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Occult blood; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Occult blood ; To Normal or No Change	14 Participants	13 Participants	10 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Occult blood; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Occult blood To Abnormal	1 Participants	2 Participants	4 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Protein; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Protein; To Normal or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Protein; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Protein To Abnormal	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Specific gravity; To Normal or No Change	14 Participants	15 Participants	12 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Specific gravity; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Specific gravity To Abnormal	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Urine pH; To Low	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Urine pH; To Normal or No Change	15 Participants	15 Participants	14 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Urine pH; To High	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria Urine pH; To Abnormal	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Day -2; Day -1; Pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1

Population: Safety Population

SBP and DBP of participants were measured in supine position after 10 minutes rest at indicated time points.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1

Population: Safety Population

SBP and DBP were measured in supine position after 10 minutes rest for the participant at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Slope of Pre-dose Concentration of GSK2838232 Administered as Non-boosted Once-daily Doses of a Tablet Formulation to Assess Achievement of Steady State Pre-dose, Days 3-11	-0.00910 Nanograms per milliliter per study day Interval -0.0239 to 0.00574	—	—
Part 2: Slope of Pre-dose Concentration of GSK2838232 Administered as Non-boosted Once-daily Doses of a Tablet Formulation to Assess Achievement of Steady State Pre-dose, Days 4-11	-0.0150 Nanograms per milliliter per study day Interval -0.0337 to 0.00377	—	—
Part 2: Slope of Pre-dose Concentration of GSK2838232 Administered as Non-boosted Once-daily Doses of a Tablet Formulation to Assess Achievement of Steady State Pre-dose, Days 5-11	-0.0379 Nanograms per milliliter per study day Interval -0.0584 to 0.0174	—	—
Part 2: Slope of Pre-dose Concentration of GSK2838232 Administered as Non-boosted Once-daily Doses of a Tablet Formulation to Assess Achievement of Steady State Pre-dose, Days 6-11	-0.0490 Nanograms per milliliter per study day Interval -0.0717 to -0.0263	—	—
Part 2: Slope of Pre-dose Concentration of GSK2838232 Administered as Non-boosted Once-daily Doses of a Tablet Formulation to Assess Achievement of Steady State Pre-dose, Days 7-11	-0.0679 Nanograms per milliliter per study day Interval -0.0971 to -0.0388	—	—
Part 2: Slope of Pre-dose Concentration of GSK2838232 Administered as Non-boosted Once-daily Doses of a Tablet Formulation to Assess Achievement of Steady State Pre-dose, Days 8-11	-0.0672 Nanograms per milliliter per study day Interval -0.111 to -0.0233	—	—
Part 2: Slope of Pre-dose Concentration of GSK2838232 Administered as Non-boosted Once-daily Doses of a Tablet Formulation to Assess Achievement of Steady State Pre-dose, Days 9-11	-0.107 Nanograms per milliliter per study day Interval -0.182 to -0.0322	—	—
Part 2: Slope of Pre-dose Concentration of GSK2838232 Administered as Non-boosted Once-daily Doses of a Tablet Formulation to Assess Achievement of Steady State Pre-dose, Days 10-11	-0.263 Nanograms per milliliter per study day Interval -0.392 to -0.133	—	—

SECONDARY outcome

Population: Pharmacokinetic Population

Blood sample were collected at indicated time points to calculate accumulation ratio from AUC(0-tau) following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, AUC (0-tau) divided by Day 1, AUC (0-tau).

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Accumulation Ratio Calculated From AUC(0-tau) Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation	1.3340 Ratio of AUC Standard Deviation 0.18272	—	—

SECONDARY outcome

Population: Pharmacokinetic Population

Blood sample were collected at indicated time points to calculate accumulation ratio from Cmax following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, Cmax divided by Day 1, Cmax.

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Accumulation Ratio Calculated From Cmax Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation	1.2118 Ratio of Cmax Standard Deviation 0.28582	—	—

SECONDARY outcome

Population: Pharmacokinetic Population

Blood sample were collected at indicated time points to calculate accumulation ratio from Ctau following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, Ctau divided by Day 1, Ctau.

Outcome measures

Outcome measures
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Accumulation Ratio Calculated From Ctau Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation	1.3205 Ratio of Ctau Standard Deviation 0.32907	—	—

Adverse Events

Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Part 1: GSK 200 mg/Ritonavir Tablet Fasted

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Part 2: Placebo

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Part 2: GSK2838232 500 mg Tablet Fed

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=15 participants at risk Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=15 participants at risk Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK 200 mg/Ritonavir Tablet Fasted n=14 participants at risk Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.	Part 2: Placebo n=3 participants at risk Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.	Part 2: GSK2838232 500 mg Tablet Fed n=7 participants at risk Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.
Gastrointestinal disorders Abdominal discomfort	6.7% 1/15 • Number of events 1 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/14 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.
Gastrointestinal disorders Abdominal pain	6.7% 1/15 • Number of events 1 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/14 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.
Gastrointestinal disorders Abdominal pain lower	6.7% 1/15 • Number of events 1 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/14 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.
Gastrointestinal disorders Constipation	6.7% 1/15 • Number of events 1 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/14 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.
Gastrointestinal disorders Diarrhoea	6.7% 1/15 • Number of events 1 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/14 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.
Gastrointestinal disorders Flatulence	6.7% 1/15 • Number of events 1 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/14 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.
Gastrointestinal disorders Vomiting	6.7% 1/15 • Number of events 2 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/14 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.
General disorders Chest discomfort	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	6.7% 1/15 • Number of events 2 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/14 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.
General disorders Chills	6.7% 1/15 • Number of events 1 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/14 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.
General disorders Infusion site pain	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	6.7% 1/15 • Number of events 1 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/14 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.
Injury, poisoning and procedural complications Skin abrasion	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	6.7% 1/15 • Number of events 1 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/14 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	7.1% 1/14 • Number of events 1 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.
Nervous system disorders Headache	20.0% 3/15 • Number of events 3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/14 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.
Nervous system disorders Syncope	6.7% 1/15 • Number of events 1 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/14 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/3 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/15 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/14 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	33.3% 1/3 • Number of events 1 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.	0.00% 0/7 • Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study. SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER

Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=3 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 9	107.333 Millimeter of mercury Standard Deviation 7.2342	110.143 Millimeter of mercury Standard Deviation 8.7069	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 10	110.000 Millimeter of mercury Standard Deviation 4.0000	106.714 Millimeter of mercury Standard Deviation 8.8828	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 11, PREDOSE	107.113 Millimeter of mercury Standard Deviation 3.8626	110.333 Millimeter of mercury Standard Deviation 9.7088	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY -1	73.667 Millimeter of mercury Standard Deviation 7.5056	73.143 Millimeter of mercury Standard Deviation 4.7759	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 1, PREDOSE	65.443 Millimeter of mercury Standard Deviation 2.6925	72.333 Millimeter of mercury Standard Deviation 8.1636	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 1, 1 Hour	54.667 Millimeter of mercury Standard Deviation 3.7859	64.714 Millimeter of mercury Standard Deviation 5.8228	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 1, 4 Hours	62.000 Millimeter of mercury Standard Deviation 1.0000	63.714 Millimeter of mercury Standard Deviation 6.7507	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 2, 24 Hours	73.667 Millimeter of mercury Standard Deviation 4.0415	73.714 Millimeter of mercury Standard Deviation 6.0474	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 3, 48 Hours	66.000 Millimeter of mercury Standard Deviation 1.7321	68.000 Millimeter of mercury Standard Deviation 7.3485	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 4, 72 Hours	69.000 Millimeter of mercury Standard Deviation 2.6458	65.143 Millimeter of mercury Standard Deviation 8.3552	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 5	62.333 Millimeter of mercury Standard Deviation 4.9329	65.000 Millimeter of mercury Standard Deviation 7.3258	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 6	62.667 Millimeter of mercury Standard Deviation 4.5092	66.143 Millimeter of mercury Standard Deviation 6.6690	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 7	64.333 Millimeter of mercury Standard Deviation 3.0551	67.286 Millimeter of mercury Standard Deviation 4.8892	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 8	66.000 Millimeter of mercury Standard Deviation 2.6458	69.286 Millimeter of mercury Standard Deviation 6.3957	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 9	69.000 Millimeter of mercury Standard Deviation 4.0000	66.714 Millimeter of mercury Standard Deviation 5.0568	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 10	65.000 Millimeter of mercury Standard Deviation 7.2111	66.571 Millimeter of mercury Standard Deviation 8.0593	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 11, PREDOSE	65.333 Millimeter of mercury Standard Deviation 5.1316	67.000 Millimeter of mercury Standard Deviation 8.0179	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 11, 1 Hour	62.667 Millimeter of mercury Standard Deviation 7.3711	66.571 Millimeter of mercury Standard Deviation 7.6563	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 11, 4 Hours	63.333 Millimeter of mercury Standard Deviation 4.5092	65.571 Millimeter of mercury Standard Deviation 8.5021	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 11, 24 Hours	67.667 Millimeter of mercury Standard Deviation 4.5092	64.714 Millimeter of mercury Standard Deviation 7.0643	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 11, 48 Hours	66.000 Millimeter of mercury Standard Deviation 5.5678	68.000 Millimeter of mercury Standard Deviation 8.9815	—
Part 2: Blood Pressure at Indicated Time Points DBP; DAY 11, 72 Hours	66.333 Millimeter of mercury Standard Deviation 3.7859	65.000 Millimeter of mercury Standard Deviation 5.8878	—
Part 2: Blood Pressure at Indicated Time Points DBP; Follow-Up (DAY 25)	71.000 Millimeter of mercury Standard Deviation 1.0000	76.143 Millimeter of mercury Standard Deviation 10.5424	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY -1	121.000 Millimeter of mercury Standard Deviation 4.5826	123.000 Millimeter of mercury Standard Deviation 7.3258	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 1, PREDOSE	107.553 Millimeter of mercury Standard Deviation 4.1400	121.190 Millimeter of mercury Standard Deviation 10.8374	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 8	105.667 Millimeter of mercury Standard Deviation 4.1633	109.571 Millimeter of mercury Standard Deviation 6.2412	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 1, 1 Hour	99.333 Millimeter of mercury Standard Deviation 2.0817	113.000 Millimeter of mercury Standard Deviation 8.7178	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 1, 4 Hours	105.000 Millimeter of mercury Standard Deviation 8.1854	106.286 Millimeter of mercury Standard Deviation 9.6214	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 2, 24 Hours	110.667 Millimeter of mercury Standard Deviation 7.7675	113.286 Millimeter of mercury Standard Deviation 5.0568	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 3, 48 Hours	111.333 Millimeter of mercury Standard Deviation 2.3094	111.714 Millimeter of mercury Standard Deviation 8.7695	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 4, 72 Hours	108.333 Millimeter of mercury Standard Deviation 7.6376	109.000 Millimeter of mercury Standard Deviation 8.2260	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 5	105.667 Millimeter of mercury Standard Deviation 2.3094	109.000 Millimeter of mercury Standard Deviation 3.0551	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 6	106.667 Millimeter of mercury Standard Deviation 4.7258	107.857 Millimeter of mercury Standard Deviation 9.0079	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 7	103.333 Millimeter of mercury Standard Deviation 1.1547	112.143 Millimeter of mercury Standard Deviation 8.6106	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 11, 1 Hour	113.000 Millimeter of mercury Standard Deviation 3.4641	111.571 Millimeter of mercury Standard Deviation 15.7041	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 11, 4 Hours	108.667 Millimeter of mercury Standard Deviation 6.0277	109.857 Millimeter of mercury Standard Deviation 8.7069	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 11, 24 Hours	107.333 Millimeter of mercury Standard Deviation 13.2035	105.143 Millimeter of mercury Standard Deviation 7.7337	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 11, 48 Hours	109.667 Millimeter of mercury Standard Deviation 8.0829	109.286 Millimeter of mercury Standard Deviation 8.8828	—
Part 2: Blood Pressure at Indicated Time Points SBP; DAY 11, 72 Hours	110.333 Millimeter of mercury Standard Deviation 2.3094	110.286 Millimeter of mercury Standard Deviation 7.6966	—
Part 2: Blood Pressure at Indicated Time Points SBP; Follow-Up (DAY 25)	115.667 Millimeter of mercury Standard Deviation 5.8595	123.714 Millimeter of mercury Standard Deviation 10.6413	—

Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=3 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=7 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 2: Change From Baseline in Blood Pressure DBP; DAY 1, 1 Hour	-10.777 Millimeter of mercury Standard Deviation 4.6690	-7.619 Millimeter of mercury Standard Deviation 4.9086	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 1, 4 Hours	-3.443 Millimeter of mercury Standard Deviation 3.6851	-8.619 Millimeter of mercury Standard Deviation 9.3099	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 2, 24 Hours	8.223 Millimeter of mercury Standard Deviation 2.5455	1.381 Millimeter of mercury Standard Deviation 5.6866	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 3, 48 Hours	0.557 Millimeter of mercury Standard Deviation 4.3485	-4.333 Millimeter of mercury Standard Deviation 8.5244	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 4, 72 Hours	3.557 Millimeter of mercury Standard Deviation 2.2180	-7.190 Millimeter of mercury Standard Deviation 8.9524	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 5	-3.110 Millimeter of mercury Standard Deviation 2.8366	-7.333 Millimeter of mercury Standard Deviation 10.9039	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 6	-2.777 Millimeter of mercury Standard Deviation 3.7175	-6.190 Millimeter of mercury Standard Deviation 7.8255	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 7	-1.110 Millimeter of mercury Standard Deviation 4.4381	-5.047 Millimeter of mercury Standard Deviation 8.9388	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 8	0.557 Millimeter of mercury Standard Deviation 0.5095	-3.047 Millimeter of mercury Standard Deviation 9.4939	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 9	3.557 Millimeter of mercury Standard Deviation 5.5901	-5.619 Millimeter of mercury Standard Deviation 8.5770	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 10	-0.443 Millimeter of mercury Standard Deviation 5.3488	-5.761 Millimeter of mercury Standard Deviation 10.0756	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 11, PREDOSE	-0.110 Millimeter of mercury Standard Deviation 3.4708	-5.333 Millimeter of mercury Standard Deviation 11.3081	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 11, 1 Hour	-2.777 Millimeter of mercury Standard Deviation 5.3385	-5.761 Millimeter of mercury Standard Deviation 12.2366	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 11, 4 Hours	-2.110 Millimeter of mercury Standard Deviation 3.3729	-6.761 Millimeter of mercury Standard Deviation 10.3364	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 11, 24 Hours	2.223 Millimeter of mercury Standard Deviation 5.9279	-7.619 Millimeter of mercury Standard Deviation 10.1445	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 11, 48 Hours	0.557 Millimeter of mercury Standard Deviation 6.7022	-4.333 Millimeter of mercury Standard Deviation 9.7243	—
Part 2: Change From Baseline in Blood Pressure DBP; DAY 11, 72 Hours	0.890 Millimeter of mercury Standard Deviation 4.6224	-7.333 Millimeter of mercury Standard Deviation 9.2678	—
Part 2: Change From Baseline in Blood Pressure DBP; Follow-Up (DAY 25)	5.557 Millimeter of mercury Standard Deviation 3.2015	3.810 Millimeter of mercury Standard Deviation 10.1939	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 1, 1 Hour	-8.220 Millimeter of mercury Standard Deviation 3.0060	-8.190 Millimeter of mercury Standard Deviation 10.8776	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 1, 4 Hours	-2.553 Millimeter of mercury Standard Deviation 5.6718	-14.904 Millimeter of mercury Standard Deviation 8.2260	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 2, 24 Hours	3.113 Millimeter of mercury Standard Deviation 5.8232	-7.904 Millimeter of mercury Standard Deviation 8.7636	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 3, 48 Hours	3.780 Millimeter of mercury Standard Deviation 1.8347	-9.476 Millimeter of mercury Standard Deviation 6.2626	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 4, 72 Hours	0.780 Millimeter of mercury Standard Deviation 5.4181	-12.190 Millimeter of mercury Standard Deviation 7.1567	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 5	-1.887 Millimeter of mercury Standard Deviation 3.6851	-12.190 Millimeter of mercury Standard Deviation 11.9632	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 6	-0.887 Millimeter of mercury Standard Deviation 7.0661	-13.333 Millimeter of mercury Standard Deviation 15.5386	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 7	-4.220 Millimeter of mercury Standard Deviation 3.7452	-9.047 Millimeter of mercury Standard Deviation 13.8084	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 8	-1.887 Millimeter of mercury Standard Deviation 5.1225	-11.619 Millimeter of mercury Standard Deviation 11.8726	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 9	-0.220 Millimeter of mercury Standard Deviation 6.1657	-11.047 Millimeter of mercury Standard Deviation 14.9222	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 10	2.447 Millimeter of mercury Standard Deviation 7.8192	-14.476 Millimeter of mercury Standard Deviation 13.8688	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 11, PREDOSE	-0.440 Millimeter of mercury Standard Deviation 4.4381	-10.857 Millimeter of mercury Standard Deviation 13.9763	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 11, 1 Hour	5.447 Millimeter of mercury Standard Deviation 6.6678	-9.619 Millimeter of mercury Standard Deviation 19.6856	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 11, 4 Hours	1.113 Millimeter of mercury Standard Deviation 2.6962	-11.333 Millimeter of mercury Standard Deviation 14.3479	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 11, 24 Hours	-0.220 Millimeter of mercury Standard Deviation 13.2912	-16.047 Millimeter of mercury Standard Deviation 15.2791	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 11, 48 Hours	2.113 Millimeter of mercury Standard Deviation 12.0648	-11.904 Millimeter of mercury Standard Deviation 11.8344	—
Part 2: Change From Baseline in Blood Pressure SBP; DAY 11, 72 Hours	2.780 Millimeter of mercury Standard Deviation 1.8347	-10.904 Millimeter of mercury Standard Deviation 13.1590	—
Part 2: Change From Baseline in Blood Pressure SBP; Follow-Up (DAY 25)	8.113 Millimeter of mercury Standard Deviation 4.6808	2.524 Millimeter of mercury Standard Deviation 10.1553	—

Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted n=14 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 1: Blood Pressure at Indicated Time Points SBP; DAY -1	110.067 Millimeter of mercury Standard Deviation 10.2153	104.000 Millimeter of mercury Standard Deviation 9.7980	108.429 Millimeter of mercury Standard Deviation 11.1128
Part 1: Blood Pressure at Indicated Time Points SBP; DAY 1, PREDOSE	108.156 Millimeter of mercury Standard Deviation 9.2400	108.289 Millimeter of mercury Standard Deviation 11.1021	106.858 Millimeter of mercury Standard Deviation 9.5900
Part 1: Blood Pressure at Indicated Time Points DBP; DAY -2	68.667 Millimeter of mercury Standard Deviation 6.2981	69.533 Millimeter of mercury Standard Deviation 7.6426	65.000 Millimeter of mercury Standard Deviation 6.1893
Part 1: Blood Pressure at Indicated Time Points DBP; DAY -1	67.467 Millimeter of mercury Standard Deviation 6.2320	68.467 Millimeter of mercury Standard Deviation 8.7657	65.643 Millimeter of mercury Standard Deviation 7.7619
Part 1: Blood Pressure at Indicated Time Points DBP; DAY 1, PREDOSE	65.956 Millimeter of mercury Standard Deviation 4.9419	66.245 Millimeter of mercury Standard Deviation 7.1653	66.929 Millimeter of mercury Standard Deviation 7.4379
Part 1: Blood Pressure at Indicated Time Points DBP; DAY 1, 1 Hour	63.200 Millimeter of mercury Standard Deviation 6.1551	64.133 Millimeter of mercury Standard Deviation 6.1163	67.357 Millimeter of mercury Standard Deviation 5.4998
Part 1: Blood Pressure at Indicated Time Points DBP; DAY 1, 2 Hours	62.133 Millimeter of mercury Standard Deviation 5.6552	62.533 Millimeter of mercury Standard Deviation 4.6425	66.071 Millimeter of mercury Standard Deviation 7.1410
Part 1: Blood Pressure at Indicated Time Points DBP; DAY 1, 4 Hours	63.733 Millimeter of mercury Standard Deviation 6.6490	64.400 Millimeter of mercury Standard Deviation 5.3825	67.429 Millimeter of mercury Standard Deviation 5.5152
Part 1: Blood Pressure at Indicated Time Points DBP; DAY 1, 6 Hours	64.400 Millimeter of mercury Standard Deviation 6.1968	64.067 Millimeter of mercury Standard Deviation 7.4878	66.071 Millimeter of mercury Standard Deviation 5.5117
Part 1: Blood Pressure at Indicated Time Points DBP; DAY 1, 8 Hours	68.333 Millimeter of mercury Standard Deviation 6.6940	66.933 Millimeter of mercury Standard Deviation 5.0351	68.000 Millimeter of mercury Standard Deviation 6.1269
Part 1: Blood Pressure at Indicated Time Points DBP; DAY 1, 12 Hours	68.867 Millimeter of mercury Standard Deviation 5.5532	67.800 Millimeter of mercury Standard Deviation 7.2723	66.214 Millimeter of mercury Standard Deviation 5.1766
Part 1: Blood Pressure at Indicated Time Points DBP; DAY 1, 24 Hours	68.400 Millimeter of mercury Standard Deviation 6.4343	66.533 Millimeter of mercury Standard Deviation 6.2663	66.929 Millimeter of mercury Standard Deviation 7.0870
Part 1: Blood Pressure at Indicated Time Points DBP; DAY 1, 48 Hours	66.600 Millimeter of mercury Standard Deviation 7.4431	67.333 Millimeter of mercury Standard Deviation 5.5377	64.643 Millimeter of mercury Standard Deviation 6.1595
Part 1: Blood Pressure at Indicated Time Points DBP; DAY 1, 72 Hours	66.600 Millimeter of mercury Standard Deviation 8.0250	67.067 Millimeter of mercury Standard Deviation 5.2026	64.429 Millimeter of mercury Standard Deviation 7.1545
Part 1: Blood Pressure at Indicated Time Points SBP; DAY -2	108.667 Millimeter of mercury Standard Deviation 9.9115	109.733 Millimeter of mercury Standard Deviation 9.0116	105.786 Millimeter of mercury Standard Deviation 9.8775
Part 1: Blood Pressure at Indicated Time Points SBP; DAY 1, 1 Hour	106.000 Millimeter of mercury Standard Deviation 10.0428	108.400 Millimeter of mercury Standard Deviation 8.3820	106.500 Millimeter of mercury Standard Deviation 9.3377
Part 1: Blood Pressure at Indicated Time Points SBP; DAY 1, 2 Hours	104.867 Millimeter of mercury Standard Deviation 10.6091	105.067 Millimeter of mercury Standard Deviation 9.6323	106.214 Millimeter of mercury Standard Deviation 11.8593
Part 1: Blood Pressure at Indicated Time Points SBP; DAY 1, 4 Hours	107.733 Millimeter of mercury Standard Deviation 9.1844	106.000 Millimeter of mercury Standard Deviation 8.8237	106.714 Millimeter of mercury Standard Deviation 10.8019
Part 1: Blood Pressure at Indicated Time Points SBP; DAY 1, 6 Hours	108.333 Millimeter of mercury Standard Deviation 8.9894	106.933 Millimeter of mercury Standard Deviation 7.1661	108.214 Millimeter of mercury Standard Deviation 11.8008
Part 1: Blood Pressure at Indicated Time Points SBP; DAY 1, 8 Hours	112.067 Millimeter of mercury Standard Deviation 8.9639	110.600 Millimeter of mercury Standard Deviation 12.3508	106.000 Millimeter of mercury Standard Deviation 12.3973
Part 1: Blood Pressure at Indicated Time Points SBP; DAY 1, 12 Hours	110.133 Millimeter of mercury Standard Deviation 10.2181	113.000 Millimeter of mercury Standard Deviation 11.9762	107.786 Millimeter of mercury Standard Deviation 12.1919
Part 1: Blood Pressure at Indicated Time Points SBP; DAY 1, 24 Hours	106.200 Millimeter of mercury Standard Deviation 9.9441	107.467 Millimeter of mercury Standard Deviation 10.8619	105.500 Millimeter of mercury Standard Deviation 11.1061
Part 1: Blood Pressure at Indicated Time Points SBP; DAY 1, 48 Hours	106.867 Millimeter of mercury Standard Deviation 10.1620	107.067 Millimeter of mercury Standard Deviation 6.3860	102.000 Millimeter of mercury Standard Deviation 12.2725
Part 1: Blood Pressure at Indicated Time Points SBP; DAY 1, 72 Hours	104.067 Millimeter of mercury Standard Deviation 11.7075	105.933 Millimeter of mercury Standard Deviation 10.8197	107.429 Millimeter of mercury Standard Deviation 13.5290

Measure	Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed n=15 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.	Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted n=14 Participants Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.
Part 1: Change From Baseline in Blood Pressure DBP; DAY 1, 1 Hour	-2.756 Millimeter of mercury Standard Deviation 4.5583	-2.112 Millimeter of mercury Standard Deviation 5.8242	0.429 Millimeter of mercury Standard Deviation 6.2950
Part 1: Change From Baseline in Blood Pressure DBP; DAY 1, 2 Hours	-3.823 Millimeter of mercury Standard Deviation 4.8274	-3.712 Millimeter of mercury Standard Deviation 7.5868	-0.857 Millimeter of mercury Standard Deviation 6.0936
Part 1: Change From Baseline in Blood Pressure DBP; DAY 1, 4 Hours	-2.223 Millimeter of mercury Standard Deviation 5.1037	-1.845 Millimeter of mercury Standard Deviation 6.6186	0.500 Millimeter of mercury Standard Deviation 4.4191
Part 1: Change From Baseline in Blood Pressure DBP; DAY 1, 6 Hours	-1.556 Millimeter of mercury Standard Deviation 4.0795	-2.179 Millimeter of mercury Standard Deviation 5.8416	-0.857 Millimeter of mercury Standard Deviation 6.7412
Part 1: Change From Baseline in Blood Pressure DBP; DAY 1, 8 Hours	2.377 Millimeter of mercury Standard Deviation 3.8999	0.688 Millimeter of mercury Standard Deviation 7.8368	1.071 Millimeter of mercury Standard Deviation 4.3963
Part 1: Change From Baseline in Blood Pressure DBP; DAY 1, 12 Hours	2.911 Millimeter of mercury Standard Deviation 6.7287	1.555 Millimeter of mercury Standard Deviation 7.1028	-0.714 Millimeter of mercury Standard Deviation 6.2782
Part 1: Change From Baseline in Blood Pressure DBP; DAY 1, 24 Hours	2.444 Millimeter of mercury Standard Deviation 4.7072	0.288 Millimeter of mercury Standard Deviation 6.5408	0.000 Millimeter of mercury Standard Deviation 6.3519
Part 1: Change From Baseline in Blood Pressure DBP; DAY 1, 48 Hours	0.644 Millimeter of mercury Standard Deviation 7.9350	1.088 Millimeter of mercury Standard Deviation 8.1406	-2.286 Millimeter of mercury Standard Deviation 4.2171
Part 1: Change From Baseline in Blood Pressure DBP; DAY 1, 72 Hours	0.644 Millimeter of mercury Standard Deviation 6.4814	0.821 Millimeter of mercury Standard Deviation 6.3773	-2.500 Millimeter of mercury Standard Deviation 7.5579
Part 1: Change From Baseline in Blood Pressure SBP; DAY 1, 1 Hour	-2.156 Millimeter of mercury Standard Deviation 5.2225	0.111 Millimeter of mercury Standard Deviation 8.8653	-0.358 Millimeter of mercury Standard Deviation 7.2826
Part 1: Change From Baseline in Blood Pressure SBP; DAY 1, 2 Hours	-3.289 Millimeter of mercury Standard Deviation 8.9001	-3.222 Millimeter of mercury Standard Deviation 11.2680	-0.644 Millimeter of mercury Standard Deviation 6.9132
Part 1: Change From Baseline in Blood Pressure SBP; DAY 1, 4 Hours	-0.423 Millimeter of mercury Standard Deviation 7.3588	-2.289 Millimeter of mercury Standard Deviation 10.0523	-0.144 Millimeter of mercury Standard Deviation 8.8536
Part 1: Change From Baseline in Blood Pressure SBP; DAY 1, 6 Hours	0.177 Millimeter of mercury Standard Deviation 6.2989	-1.355 Millimeter of mercury Standard Deviation 8.9097	1.356 Millimeter of mercury Standard Deviation 9.9739
Part 1: Change From Baseline in Blood Pressure SBP; DAY 1, 8 Hours	3.911 Millimeter of mercury Standard Deviation 7.8095	2.311 Millimeter of mercury Standard Deviation 11.0679	-0.858 Millimeter of mercury Standard Deviation 10.0987
Part 1: Change From Baseline in Blood Pressure SBP; DAY 1, 12 Hours	1.977 Millimeter of mercury Standard Deviation 6.7186	4.711 Millimeter of mercury Standard Deviation 7.4998	0.928 Millimeter of mercury Standard Deviation 9.8279
Part 1: Change From Baseline in Blood Pressure SBP; DAY 1, 24 Hours	-1.956 Millimeter of mercury Standard Deviation 7.9095	-0.822 Millimeter of mercury Standard Deviation 9.2810	-1.358 Millimeter of mercury Standard Deviation 4.6289
Part 1: Change From Baseline in Blood Pressure SBP; DAY 1, 48 Hours	-1.289 Millimeter of mercury Standard Deviation 4.9058	-1.222 Millimeter of mercury Standard Deviation 10.7458	-4.858 Millimeter of mercury Standard Deviation 9.5294
Part 1: Change From Baseline in Blood Pressure SBP; DAY 1, 72 Hours	-4.089 Millimeter of mercury Standard Deviation 7.4727	-2.355 Millimeter of mercury Standard Deviation 9.9198	0.571 Millimeter of mercury Standard Deviation 11.2671